Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-04-05
2011-04-05
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C558S077000
Reexamination Certificate
active
07919481
ABSTRACT:
The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.
REFERENCES:
patent: 4192869 (1980-03-01), Nicolau et al.
patent: 4321259 (1982-03-01), Nicolau et al.
patent: 4404150 (1983-09-01), Tsunekawa et al.
patent: 4473496 (1984-09-01), Scannon
patent: 4478824 (1984-10-01), Franco et al.
patent: 4650786 (1987-03-01), Wong
patent: 4652449 (1987-03-01), Ropars et al.
patent: 4699926 (1987-10-01), Abraham et al.
patent: 4710488 (1987-12-01), Wong
patent: 4731381 (1988-03-01), Abraham et al.
patent: 4731473 (1988-03-01), Abraham et al.
patent: 4735936 (1988-04-01), Siren
patent: 4751244 (1988-06-01), Abraham et al.
patent: 4752586 (1988-06-01), Ropars et al.
patent: 4777134 (1988-10-01), Siren
patent: 4794014 (1988-12-01), Siren
patent: 4797390 (1989-01-01), Siren
patent: 4826675 (1989-05-01), Gaffar et al.
patent: 4847082 (1989-07-01), Sabin
patent: 4851560 (1989-07-01), Siren
patent: 4873355 (1989-10-01), Hobbs et al.
patent: 4874690 (1989-10-01), Goodrich, Jr. et al.
patent: 4887995 (1989-12-01), Abraham et al.
patent: 4924023 (1990-05-01), Hobbs et al.
patent: 4931276 (1990-06-01), Franco et al.
patent: 4952396 (1990-08-01), Sabin et al.
patent: 4952717 (1990-08-01), Ozaki et al.
patent: 5003098 (1991-03-01), Siren et al.
patent: 5015634 (1991-05-01), Siren
patent: 5019566 (1991-05-01), Siren
patent: 5023248 (1991-06-01), Siren
patent: 5043261 (1991-08-01), Goodrich et al.
patent: 5051411 (1991-09-01), Siren
patent: 5057507 (1991-10-01), Siren
patent: 5082833 (1992-01-01), Shamsuddin
patent: 5091549 (1992-02-01), Ozaki et al.
patent: 5135923 (1992-08-01), Siren
patent: 5151539 (1992-09-01), Bright et al.
patent: 5210263 (1993-05-01), Kozikowski et al.
patent: 5252707 (1993-10-01), Ozaki et al.
patent: 5260287 (1993-11-01), Barreto et al.
patent: 5260472 (1993-11-01), Chen
patent: 5264605 (1993-11-01), Ozaki et al.
patent: 5274161 (1993-12-01), Siren et al.
patent: 5292913 (1994-03-01), Ozaki et al.
patent: 5295944 (1994-03-01), Teicher et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 5330979 (1994-07-01), Siren et al.
patent: 5344393 (1994-09-01), Roth et al.
patent: 5407924 (1995-04-01), Siren
patent: 5428007 (1995-06-01), Fischer et al.
patent: 5451205 (1995-09-01), Roth et al.
patent: 5545632 (1996-08-01), Siren
patent: 5612207 (1997-03-01), Nicolau et al.
patent: 5626884 (1997-05-01), Lockett
patent: 5720921 (1998-02-01), Meserol
patent: 5827837 (1998-10-01), Bevilacqua et al.
patent: 5846957 (1998-12-01), Siren
patent: 5866548 (1999-02-01), Tsien et al.
patent: 5866557 (1999-02-01), Persson et al.
patent: 5880099 (1999-03-01), Traynor-Kaplan et al.
patent: 5977078 (1999-11-01), Traynor-Kaplan et al.
patent: 6004938 (1999-12-01), Frick et al.
patent: 6074605 (2000-06-01), Meserol et al.
patent: 6096916 (2000-08-01), Aneja
patent: 6187335 (2001-02-01), Brey et al.
patent: 6610702 (2003-08-01), Lehn et al.
patent: 7084115 (2006-08-01), Nicolau et al.
patent: 7084126 (2006-08-01), Frey, II et al.
patent: 7618954 (2009-11-01), Nicolau et al.
patent: 7648970 (2010-01-01), Nicolau et al.
patent: 2002/0028786 (2002-03-01), Frey, II et al.
patent: 2002/0142995 (2002-10-01), Nicolau et al.
patent: 2002/0173494 (2002-11-01), Lehn et al.
patent: 2003/0017150 (2003-01-01), Torphy
patent: 2003/0147937 (2003-08-01), Schwarz
patent: 2004/0014642 (2004-01-01), Nicolau et al.
patent: 2004/0072801 (2004-04-01), Nicolau et al.
patent: 2004/0147487 (2004-07-01), Traylor-Kaplan et al.
patent: 2005/0020542 (2005-01-01), Traynor-Kaplan et al.
patent: 2005/0227946 (2005-10-01), Siren
patent: 2005/0250743 (2005-11-01), Lehn et al.
patent: 2005/0272642 (2005-12-01), Frey, II et al.
patent: 2006/0009413 (2006-01-01), Frey, II et al.
patent: 2006/0014716 (2006-01-01), Frey, II et al.
patent: 2006/0030542 (2006-02-01), Frey, II et al.
patent: 2006/0106000 (2006-05-01), Nicolau et al.
patent: 2006/0116358 (2006-06-01), Nicolau et al.
patent: 2006/0241086 (2006-10-01), Nicolau et al.
patent: 2006/0258626 (2006-11-01), Nicolau et al.
patent: 2007/0066574 (2007-03-01), Grases Freixedas
patent: 2007/0129336 (2007-06-01), Traynor-Kaplan
patent: 2007/0135389 (2007-06-01), Nicolau et al.
patent: 2007/0207986 (2007-09-01), Nicolau et al.
patent: 0 392 697 (1990-10-01), None
patent: 0 508 488 (1992-10-01), None
patent: 52107239 (1977-09-01), None
patent: 1175989 (1989-07-01), None
patent: WO 87/05598 (1987-09-01), None
patent: WO 92/20369 (1992-11-01), None
patent: WO 94/21117 (1994-09-01), None
patent: WO 95/03068 (1995-02-01), None
patent: WO 95/05830 (1995-03-01), None
patent: WO 96/32136 (1996-10-01), None
patent: WO 01/13933 (2001-03-01), None
patent: WO 01/15738 (2001-03-01), None
patent: WO 01/24830 (2001-04-01), None
patent: WO 01/82932 (2001-11-01), None
patent: WO 02/09723 (2002-02-01), None
patent: WO 02/10177 (2002-02-01), None
patent: WO 03/092700 (2003-11-01), None
patent: WO 2006/102060 (2006-09-01), None
patent: WO 2007/081315 (2007-07-01), None
Adachi et al., Nucleation-Controlled Aggregation of Deoxyhemoglobins—Effect of Organic Phosphates on the Kinetics of Aggregation of Deoxyhemoglobin S in Concentrated Phosphate Buffer, Biochimica et Biophysica Acta, vol. 624, Aug. 21, 1980, pp. 372-377.
Advances in Chemical Engineering, vol. 19, Vascular Morphology, 1994, p. 147.
Amorino et al., Enhancement of Tumor Oxygenation and Radiation Response by the Allosteric Effector of Hemoglobin, RSR13, Radiation Research, vol. 156, Oct. 12, 2000, pp. 1.
Arnone, Arthur, “X-ray Diffraction Study of Binding of 2,3-Diphosphoglycerate to Human Deoxyhaemoglobin”, Nature, vol. 237, May 19, 1972, pp. 146-149.
Benesch et al., “The Effect of Organic Phosphates from the Human Erythrocyte on the Allosteric Properties of Hemoglobin”, Biochemical and Biophysical Research Communications, vol. 26, No. 2,1967, pp. 162-167.
Benesch et al., “Intracellular Organic Phosphates as Regulators of Oxygen Release by Haemoglobin”, Nature, vol. 221, Feb. 15, 1969, pp. 618-622.
Cosgrove, D.J., The Phosphorylation of epi-Inositol and muco-Inositol with Polyphosphoric Acid, Carbohydrate Research, vol. 40, Jan. 1, 1975, pp. 380-384.
Desai et al., The Preparation, Resolution, and Phosphorylation of Some Benzyl Ethers of myo-Inositol: Intermediates for the Synthesis of myo-Inositol Phosphates of the Phosphotidylinositol Cycle, Carbohydrate Research, vol. 225, Mar. 1, 1992, pp. 209-228.
Dinkel et al., Membrane-Permeant 3-OH-Phosphorylated Phosphoinositide Derivatives, Angewandte Chemie Intenational Edition, vol. 40(16), Aug. 17, 2001, pp. 3004-3008.
EntreMed Annual Report, EDGAR Online, Mar. 3, 2000, pp. 1-40.
Fisher, Erythropoietin: Physiology and Pharmacology Update, Society for Experimental Biology and Medicine, vol. 228(1), Jan. 1, 2003, pp. 1-14.
Folkman, Models of Anti-Cancer Therapy: Angiogenesis Inhibitors: A New Class of Drugs, Cancer Biology & Therapy, vol. 2.4 Suppl. 1, pp. S127-S133, 2003.
Fylaktakidou et al., Inositol Triphosphate: A New Membrane Permeant Allosteric Effector of Haemoglobin, Bioorganic & Medicinal Chemistry Letters, vol. 15, Jan. 1, 2005, pp. 1605-1608.
Gersonde et al., “Modification of the Oxygen Affinity of Intracellular Haemoglobin by Incorporation of Polyphosphates into Intact Red Blood Cells and Enhanced 02 Release in the Capillary System”, Biblthcahaemat., No. 46, 1980, pp. 81-92.
Gutman et al., Failure of Thalidomide to Inhibit Tumor Growth and Angiogenesis in Vivo, Anticancer Research, vol. 16, Jan. 1, 1996, pp. 3673-3678.
Hockel et al., Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects, Journal of the National Cancer Institute, vol. 93(4) , Feb. 21, 2001, pp. 266-276.
Huang et al., “Identification and
Fylaktakidou Konstantina
Greferath Ruth
Lehn Jean-Marie
Nicolau Yves Claude
Cooley LLP
NormOxys, Inc.
Saeed Kamal A
LandOfFree
Inositol pyrophosphates, and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inositol pyrophosphates, and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inositol pyrophosphates, and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2735833